AgeX Therapeutics to Merge with Serina Therapeutics

(24/7 MARKET NEWS) – AgeX Therapeutics, Inc. (AGE:ASE) entered into a merger agreement with Serina Therapeutics, Inc., a privately-held, clinical-stage biotechnology company developing a pipeline of therapies for the treatment of Parkinson’s and other neurological diseases, under which Serina will merge with a wholly-owned subsidiary of AgeX in an all-stock transaction. The combined company will continue under the Serina Therapeutics name and will focus on advancing Serina’s pipeline of small molecule drug candidates targeting central nervous system (“CNS”) indications.

AgeX Therapeutics is trading at $0.78, up $0.0599 (+8.31%), on 17.6K premarket shares traded.

Its 52-week range is $0.372 to $1.00. This morning’s premarket high is $0.9101, but if it’s going to make a significant move the volume needs to pick up.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.